ReForm Biologics Inc. Announces Appointments of Kevin Kavanaugh, CPA, to Chief Financial Officer and Robert Mahoney, PhD, to Chief Scientific Officer

Oct. 13, 2021 11:00 UTC



WOBURN, Mass.--(BUSINESS WIRE)-- ReForm Biologics, a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert Mahoney, PhD, has been promoted to Chief Scientific Officer (CSO) and that Kevin Kavanaugh, CPA, has been promoted to Chief Financial Officer.

“Bob Mahoney and Kevin Kavanaugh are key members of the ReForm team and their promotions reflect not only our confidence in their leadership abilities but also a recognition of the increasingly important roles they have played in transforming ReForm into a company focused on the needs of fragile patients,” said Jeff Hackman, President and Chief Executive Officer, ReForm Biologics Inc. “Bob Mahoney has led the development of the platform that allows ReForm to reformulate biologics to improve their viscosity and stability. Kevin Kavanaugh has been an integral member of the ReForm team since the company’s inception and ensured that the company has been financially stable as it has grown and evolved into a drug development company. We look forward to the continued leadership of Kevin and Bob as ReForm pursues its mission of improving clinical outcomes, health, and well-being of tens of millions of fragile patients annually.”

Kevin P. Kavanaugh, CPA, has more than 25 years of experience in the accounting field in both corporate private and public accounting settings. Most recently, Kevin has served as ReForm’s Controller since its founding. Previously, Kevin was the Controller of Soane Labs, Transform Materials and Crop Enhancement where he engaged in multiple successful license and business agreements. Kevin has also held management roles at Burst Media, State Street Bank, and Iron Mountain, following several years in public accounting, including Ernst and Young.

Robert Mahoney, PhD, has spent 25 years leading the development of disruptive new products and processes for industries including water treatment, oilfield technologies, pharmaceuticals, agriculture, and mineral processing. Before joining ReForm, he served as VP of R&D under David Soane at Soane Energy, leading to the successful deployment of an innovative self-suspending proppant technology. Prior to joining Soane Energy, he was VP of R&D at Polymer Ventures, designing and commercializing many new specialty polymer products. Previously, Robert was responsible for development of next-generation performance additives at Nalco (now part of Ecolab), the global leader in water and process treatment chemicals. He received his PhD in physical organic chemistry from the University of Colorado at Boulder and has authored numerous patents, publications, and presentations.

About ReForm Biologics, Inc.
ReForm Biologics’ mission is to develop improved biologic formulations derived from its proprietary, patented technology platform to enhance patients’ lives, particularly for fragile populations such as children and the elderly. We are doing this by improving the viscosity and stability of known biologics, with our own formulations as well as for those of other biopharmaceutical companies to make their medicines gentler for patients.


Rob Kloppenburg
Shoreline Biotech Communications
(617) 930-5595


Source: ReForm Biologics, Inc.

Back to news